Takeda Pharmaceutical has announced that Christophe Weber has been approved at the company's Board of Directors Meeting to become Chief Operating Officer (COO) and candidate as the next Chief Executive Officer (CEO). Mr. Weber will join Takeda to take the role of COO by April 2014.
A government study offers a new theory on why the whooping cough vaccine doesn't seem to be...
The Food and Drug Administration is lifting severe safety restrictions on the former blockbuster...
The U.S. government has for the first time approved an adjuvanted vaccine to protect against...
Pfizer announced today that it has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK’s trametinib (GSK1120212) combined with Pfizer’s palbociclib (PD-0332991) in a Phase I/II study (Study 200344) in patients with advanced/metastatic melanoma.
GlaxoSmithKline says a potential heart disease treatment it acquired as part of a key 2012 company takeover fell short in the main measurement of a late-stage study. Darapladib failed to produce a statistically significant reduction in major cardiovascular events like heart attacks, strokes or death when added to a patient's standard of care.
Janssen Pharmaceuticals, Inc. announced today the acquisition of the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C, from an affiliate of GlaxoSmithKline plc. Janssen has acquired all rights to develop and commercialize GSK2336805, including in combination with other drugs.
The FDA has approved changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to add new Boxed Warning information about the risk of reactivation of hepatitis B virus (HBV) infection.
GlaxoSmithKline PLC and Dutch biotech Prosensa Holding N.V. said Friday a potential treatment for Duchenne muscular dystrophy failed in a late-stage study to produce a significant difference in patients taking the drug compared with those who had a fake version.
ChemoCentryx has announced that GlaxoSmithKline has returned to ChemoCentryx all rights to vercirnon (also known as Traficet-EN and CCX282), an inhibitor of the chemokine receptor known as CCR9, for all indications, including the treatment of inflammatory bowel disease.
GlaxoSmithKline says it has sold its line of Lucozade and Ribena drinks brands to Suntory of Japan as part of the British company's effort to focus on its core pharmaceutical and health-care businesses.
The failure of a GlaxoSmithKline cancer vaccine in a clinical trial is a setback for a hot area of medicine that seeks to harness the body’s immune system to fight tumors.
Shares of Agenus fell sharply Thursday on unsuccessful clinical trial results for a cancer treatment that included its compound that is designed to make drugs more effective. British drugmaker GlaxoSmithKline PLC is studying cancer treatments that include Agenus' SQ-21 Stimulon vaccine adjuvant....
The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.
The co-founders of a business risk advisory firm that has reportedly worked with GlaxoSmithKline have been arrested in China on suspicion of breaking laws related to purchasing personal information. British Embassy spokeswoman Hannah Oussedik confirmed Wednesday the arrest of British national Peter Humphrey on August 19, but declined to provide further details.
The FDA has approved Tivicay (dolutegravir), a new drug to treat HIV-1 infection. Tivicay is an integrase strand transfer inhibitor that interferes with one of the enzymes necessary for HIV to multiply. It is a pill taken daily in combination with other antiretroviral drugs.
Accusations this month that GlaxoSmithKline employees bribed Chinese doctors to prescribe its drugs brought international attention to the flow of illicit money. But to China's public, the practice has long been common knowledge. Many blame a system in which the country's hospitals nearly all are state-run but get too little money from Beijing.
Here’s one takeaway from the bribery scandal GlaxoSmithKline is weathering in China: In GlaxoSmithKline’s anguish, there’s solace for the Chinese consumer as the company has begun to lower prices on many of its products.
GlaxoSmithKline agreed Friday to pay Louisiana $45 million to settle lawsuits accusing it of improperly marketing the diabetes drug Avandia and other drugs. Attorneys for the state and company told state District Judge Janice Clark that GSK also will pay an additional $7 million to the private lawyers who handled the state's lawsuits against the firm.
GlaxoSmithKline has named a new chief for its operations in China amid an investigation there for possible bribery of doctors, the drug manufacturer said Thursday. Chinese police say that four employees of GSK China are suspected of paying bribes to doctors and hospitals to encourage them to prescribe medications.
GlaxoSmithKline, target of a bribery probe in China, said Monday some executives may have broken the law, while rival drug maker AstraZeneca said police are investigating one of its sales representatives. GSK said its president for Asia-Pacific and emerging markets met with Chinese police officials who are investigating whether GSK employees bribed doctors and hospital administrators to prescribe its drugs.
GlaxoSmithKline, under investigation on suspicion its employees bribed Chinese doctors, said Thursday the finance director for its local unit has been barred from leaving China.
China announced a crackdown today on misconduct in its drug market, stepping up pressure on the problem-prone industry while it pursues a bribery investigation of GlaxoSmithKline. The six-month crackdown is aimed at stamping out unauthorized drug production, improper online drug retailing and sales of fake traditional Chinese medicines, the State Food and Drug Administration said.
China’s Ministry of Public Security said four high-level executives from GlaxoSmithKline were detained on bribery charges.
Chinese police have identified four managers of drug manufacturer GlaxoSmithKline who they accuse of paying millions of dollars in bribes to doctors and others, a state news agency reported. The police ministry announced last week GSK employees were under investigation for paying bribes that were...
Chinese police have identified four executives of drug manufacturer GlaxoSmithKline who they accuse of paying millions of dollars in bribes to doctors and others.
China's police ministry said Thursday that it has found employees of drug manufacturer GlaxoSmithKline bribed doctors and hospitals to prescribe medications. Employees gave free travel as "large bribes" to doctors, hospitals, foundations and medical associations "to open new sales channels and...
Drug manufacturer GlaxoSmithKline said Thursday it has investigated an accusation that its salespeople in China bribed doctors and found no evidence of wrongdoing. The company said it conducted a four-month investigation after receiving complaints from an anonymous source.
British drugmaker GlaxoSmithKline PLC says it dismissed one employee and a second has resigned in the wake of a scandal over misrepresented data in a research paper published in 2010. The company says its investigation of recent allegations of questionable data has established that some...
- Page 1